drugset / Trial / NCT06332287

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis

NCT06332287

Phase 2 Unknown 25 enrolled Jiangsu Province Nanjing Brain Hospital
NaSingle-groupOpen-labelTreatment

Summary

To observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the treatment of non-small cell lung cancer with leptomeningeal metastasis。

Timeline

Start
2023-05-01
Primary completion
2024-11-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Trilaciclib Unknown 240 mg/m2
Background Pemetrexed Small molecule 30 mg